About Julia Hayes
Prostate Specific Antigen (PSA) screening is widely used to assist the early diagnosis of prostate cancer. However, benefits of PSA screening are controversial. Dr. Hayes proposes to develop a model that assesses the effect of PSA screening on overall life expectancy and quality of life, and measures PSA screening cost-effectiveness. To accomplish this, she will use large cohorts of existing data from both the United States and Europe that have detailed records of patients who have undergone PSA screening and those who have not. This research will inform clinical decision making and guide future clinical research and health policy.
The 2010 Ressler-Gertz Family Foundation – PCF Young Investigator Award
Julia Hayes, MD
Dana-Farber Cancer Institute – Boston, MA
Philip Kantoff, MD, Chief Clinical Research Officer, Director of the Lank Center of Genitourinary Oncology and Chief of the Division of Solid Tumor Oncology at Dana-Farber Cancer Institute.
Michael Barry, MD, Director of the Health Services Research Program and Chief of the General Medicine Unit at Massachusetts General Hospital.